Free · no account · quoted from the filing

What changed in JNJ's 10-Q

Source: 10-Q filed 2026-07-23 · compared against 10-Q 2026-04-22. Every passage below is quoted verbatim from the filing itself.

Demand verified

Prior filing

worldwide sales were $24.1 billion, a total increase of 9.9%, which included operational* growth of 6.4%

This filing

worldwide sales were $25.3 billion, a total increase of 6.6%, which included operational growth of 5.6%

Demand verified

Prior filing

the negative impact of the STELARA sales decline, due to biosimilar competition, on worldwide operational sales was approximately 5.4%

This filing

the negative impact of the STELARA sales decline, due to biosimilar competition, on worldwide operational sales was approximately 4.6%

Demand verified

Prior filing

the net impact of acquisitions and divestitures on worldwide operational sales growth was a positive 1.1%

This filing

the net impact of acquisitions and divestitures on worldwide operational sales growth was a negative 0.1%

Margins verified

Prior filing

Cost of products sold 8,106 33.7

This filing

Cost of products sold 8,051 31.8

Liquidity verified

Prior filing

Loans and notes payable $17,460 8,495

This filing

Loans and notes payable $11,692 8,495

Segments verified

Prior filing

Goodwill, related to acquisitions — — —

This filing

Goodwill, related to acquisitions — 3 3

What it means — the analyst reading

The passages above are the company's own words. The plain-English reading of them — what changed, why it matters, and the direction of travel — is part of the Filing Change Monitor.

See the Filing Change Monitor →

Compared from narrative excerpts (outlook, risks, MD&A) of both filings. Every quotation shown was checked character-for-character against the filing it is attributed to. Not advice. Source: company SEC filings via stockportfolio.pro. Educational, not investment advice.